3 Stocks in Takeover Talks – Week of 10/22

Takeover deals can be a signal of positive market sentiment, indicating that the acquiring company is confident in its growth prospects and is willing to invest in expanding its market share. Such deals often lead to an increase in stock prices as they indicate potential value creation and synergies for the acquiring company. Takeover deals may provide an opportunity for investors to capitalize on market inefficiencies and earn profits through arbitrage strategies, such as buying the target company’s stock at a discount to the offer price and profiting from the price convergence upon deal completion.

Here are three takeover targets for the week –

Sharecare, Inc. – SYM: SHCR
Recent Price: $1.16
Takeover Action: According to an amended 13D filing Sharecare board member John Chadwick, on behalf of Claritas Capital, submitted a preliminary non-binding proposal to purchase the company’s shares for cash consideration of between $1.35 and $1.80 a share. Sharecare has confirmed receipt of an unsolicited proposal from Claritas Captial.
Description: Sharecare, Inc. operates as a digital healthcare platform company. Its Sharecare platform connects people, patients, providers, employers, health plans, government organizations, and communities that optimize individual and population-wide well-being. The company was founded in 2009 and is headquartered in Atlanta, Georgia.

#1 Small-Cap Uranium Stock to Buy Before November!

The New Uranium Bull Market has officially arrived with prices obliterating decade highs.

It’s just like last time when uranium prices roared past $140/lb!

Well-positioned investors are ALREADY making a killing on select uranium stocks.

Get all the details in our brand new FREE online report.


LL Flooring Holdings, Inc. – SYM: LL
Recent Price: $3.13
Takeover Action: U.S. investment firm Live Ventures (LIVE) has offered to buy LL Flooring Holdings (LL), formerly known as Lumber Liquidators, for roughly $180 million in cash.
Description: LL Flooring Holdings, Inc., together with its subsidiaries, operates as a multi-channel specialty retailer of hard-surface flooring, and hard-surface flooring enhancements and accessories. The company offers hard-surface flooring including, waterproof hybrid resilient, waterproof vinyl plank, engineered hardwood, laminate, bamboo, tile, and cork products; and flooring enhancements and accessories, including moldings, underlayment, adhesives, and tools under the Bellawood and Coreluxe brand names. It also provides in-home delivery and installation services. The company also offers its products through stores, digital platform, and catalogs. The company was formerly known as Lumber Liquidators Holdings, Inc. and changed its name to LL Flooring Holdings, Inc. in January 2022. LL Flooring Holdings, Inc. was founded in 1994 and is headquartered in Richmond, Virginia.

What is Biden doing to Bitcoin?


Recent Securities and Exchange Commission lawsuits against Coinbase and Binance have created confusion in the crypto market.

One headline even asked if the Biden administration was trying to kill crypto altogether.

But, if you look closer, there’s something else going on here.

Something that could send Bitcoin prices over $100,000.

This isn’t a bad time to buy crypto.

It’s the best time.


Prothena Corporation plc – SYM: PRTA
Recent Price: $45.57
Takeover Action: According to Bloomberg, Prothena Corp. (PRTA), which is developing a closely-watched treatment for Alzheimer’s disease, is preparing for a potential sale.
Description: Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Viral Silicon Valley video reveals new AI cash cow

cash cow

Did you see this new viral AI video?

On camera, one of America’s top tech analysts, Colin Tedards, reveals the next AI cash cow…

A groundbreaking technology The Wall Street Journal calls, “the lifeblood of AI.”

It has nothing to do with Nvidia or any popular tech company.

But firms like Tesla, Microsoft, and OpenAI – the company behind ChatGPT – are buzzing about this groundbreaking technology right now.

For early investors, this tiny new device could unlock $200 trillion in AI profits.

Click here to see this viral video before it gets taken down.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.